Sökning: WFRF:(Nordstrom Johan L) >
Comparison of treat...
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis
-
- Lindström, Ulf (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Sahlgrenska Academy
-
- Glintborg, B. (författare)
- University of Copenhagen,Copenhagen University Hospital
-
- Di Giuseppe, D. (författare)
- Karolinska Institute,Karolinska Institutet
-
visa fler...
-
- Jorgensen, T. S. (författare)
- Copenhagen University Hospital
-
- Gudbjornsson, B. (författare)
- National University Hospital of Iceland
-
- Gron, K. L. (författare)
- Copenhagen University Hospital
-
- Provan, S. A. (författare)
- Diakonhjemmet Hospital
-
- Michelsen, B. (författare)
- Diakonhjemmet Hospital,Sørlandet Hospital
-
- Hetland, M. L. (författare)
- Copenhagen University Hospital,University of Copenhagen
-
- Wallman, Johan K. (författare)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital
-
- Nordstrom, D. (författare)
- Helsinki University Central Hospital
-
- Trokovic, N. (författare)
- University of Helsinki
-
- Love, T. J. (författare)
- National University Hospital of Iceland
-
- Krogh, N. S. (författare)
- Zitelab Aps
-
- Askling, J. (författare)
- Karolinska Institute,Karolinska Institutet
-
- Jacobsson, Lennart T. H., 1954 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Sahlgrenska Academy
-
- Kristensen, L. E. (författare)
- Copenhagen University Hospital
-
visa färre...
-
(creator_code:org_t)
- 2020-12-26
- 2021
- Engelska.
-
Ingår i: Rheumatology. - : Oxford University Press (OUP). - 1462-0324 .- 1462-0332. ; 60:8, s. 3635-3645
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives. To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA. Methods. All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+). Results. We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar. Conclusion. No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Nyckelord
- psoriatic arthritis
- treatment
- secukinumab
- adalimumab
- retention
- response
- adalimumab
- Rheumatology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lindström, Ulf
-
Glintborg, B.
-
Di Giuseppe, D.
-
Jorgensen, T. S.
-
Gudbjornsson, B.
-
Gron, K. L.
-
visa fler...
-
Provan, S. A.
-
Michelsen, B.
-
Hetland, M. L.
-
Wallman, Johan K ...
-
Nordstrom, D.
-
Trokovic, N.
-
Love, T. J.
-
Krogh, N. S.
-
Askling, J.
-
Jacobsson, Lenna ...
-
Kristensen, L. E ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Reumatologi och ...
- Artiklar i publikationen
-
Rheumatology
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet
-
Lunds universitet